×
<- Back

First use of Creatine Hydrochloride in Premanifest Huntington Disease

  • : Online

Huntington disease is a devastating autosomal dominant neurodegenerative disorder that typically manifests between ages 30 and 50 years. Promising high-dose creatine monophosphate trials have been limited by patient tolerance.

This is the first report of use of creatine hydrochloride in two premanifest Huntington disease patients, with excellent tolerability over more than 2 years of use.

Learning Outcomes

  • Understand of treatment outcomes with creatine hydrochloride in two premanifest Huntington disease patients
  • Provider name

    Medical Journal of Australia

    Provider number

    N/A

    Type

    Reading: journal; textbook; book; literature review

    Duration

    0h : 30m

    CPD Points/Hours

    MBA: 0h : 30m

    Topic

    Medical Genetics

    Audience

    Medical Practitioner, Medical Student, Doctor-in-Training, Non-Vocationally Registered, Pharmacist, Researcher, Retired, Specialist - Other, Specialist General Practitioner

    Delivery
    Title
    First use of Creatine Hydrochloride in Premanifest Huntington Disease
    Interest Areas / Topics Covered
    Genetics
    Location
    Provider Type
    Education Provider
    Duration
    30 minutes
    CPD Points
    MBA: 0h : 30m
    Price
    Free
    Location
    Online
    Contact Phone
    Log in into view this field.
    Cover Picture 257_first_use_of_creatine_hydrochloride1601959945.png
    44 Views
    HealthcareLink